Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
15/07/2025 12:00
July 15 (Reuters) - Hong Kong-listed Sino Biopharmaceutical 1177.HK said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 million. (Reporting by Shivangi Lahiri in Bengaluru; Editing by Mrigank Dhaniwala) ((Shivangi.Lahiri@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit